Pattern Alopecia during Hormonal Anticancer Therapy in Patients with Breast Cancer

Park, Jin; Kim, Ju Ik; Yun, Seok Kweon; Kim, Han Uk; Ihm, Chull Wan

doi:10.5021/ad.2014.26.6.743

Cited by 11 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many hormones, including the thyroid, adrenal, pineal and pituitary gland hormones, impact the hair growth cycle [28]. Oestrogens are usually believed to have protective qualities [3,29,30], even though some studies indicate that hair growth is slowed under their influence due to the initiation of an earlier catagen phase, and prolongation of telogen phase [31].…”

Section: Discussionmentioning

confidence: 99%

The role of CYP19A1 and ESR2 gene polymorphisms in female androgenetic alopecia in the Polish population

Łukasik¹,

Kozicka²,

Pisarek³

et al. 2022

pdia

View full text Add to dashboard Cite

Introduction: Androgenetic alopecia is the most common type of non-cicatricial alopecia both in male and female patients. The mechanism that leads to hair loss is similar in both sexes, but the underlying cause, and especially the role of genes and sex hormones in the pathogenesis of the disease in women has not fully been explained as of yet. So far, a few attempts have been made to assess selected SNPs for CYP19A1 and ESR2 genes, but their results are not unequivocal and fully reproducible. Aim: To investigate the association of 13 CYP19A1 and 11 ESR2 gene SNPs with female androgenetic alopecia (FAGA) in a population of Polish patients, including some already genotyped SNPs of possible importance for FAGA pathophysiology in other populations. Material and methods: Twenty-four genetic polymorphisms were analysed for the ESR2 and CYP19A1 genes in 117 patients with FAGA and 128 healthy subjects treated at the Department of Dermatology in Krakow. Results: In the studied Polish population, none of the selected SNPs, frequently detected in the Caucasian population and linked with the transformation pathway of sex hormones, showed a significant association with FAGA. Conclusions: Further studies into the genetic background of androgenetic alopecia are needed. Ethnic differences as well as the size of the studied population may be of great significance for the obtained results.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of CYP19A1 and ESR2 gene polymorphisms in female androgenetic alopecia in the Polish population

Łukasik¹,

Kozicka²,

Pisarek³

et al. 2022

pdia

View full text Add to dashboard Cite

show abstract

“…Clinically, a progressive recession of frontal-temporal hairline is present, associated with a certain grade of hair miniaturization in the same area and also in the central area of the scalp [6][7][8][9][10]. It develops within 12 months of HT in most cases.…”

Section: Clinical Aspect Of Alopecia Induced By Ht For Breast Cancermentioning

confidence: 99%

Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer

Rossi

Caro

Magri

et al. 2021

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizing hormone-releasing hormone analogs. In patients receiving these drugs, a progressive recession of frontal-temporal hairlines is often observed, such as a certain grade of hair miniaturization in the same areas and the central scalp area, producing a pseudo-female androgenic alopecia, which has to be considered oncotherapy-induced alopecia. The aim of this work, is to describe the clinical aspects and pathogenesis of this type of alopecia and to analyze the different drugs which have been proposed until now. The authors concude that topical hormones should not be considered as a therapeutic approach because of their direct or indirect oncogenic potential. A therapeutic approach that could be both safe and effective is proposed.

show abstract

“…Because ETIHL negatively affects sociocultural status and quality of life, it is a major problem and remains a therapeutic challenge in patients with breast cancer. Supplementation with vitamins (D, E, C, folic acid) and/or omega-3 fatty acids has been a popular adjuvant therapy, often associated in combination with minoxidil [ 35 , 56 ].…”

Section: Endocrine Therapy-induced Hair Loss (Etihl)mentioning

confidence: 99%

The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy

Dell'Acqua¹,

Richards²,

Thornton

2020

Nutrients

View full text Add to dashboard Cite

Nutraceuticals, natural dietary and botanical supplements offering health benefits, provide a basis for complementary and alternative medicine (CAM). Use of CAM by healthy individuals and patients with medical conditions is rapidly increasing. For the majority of breast cancer patients, treatment plans involve 5–10 yrs of endocrine therapy, but hair loss/thinning is a common side effect. Many women consider this significant, severely impacting on quality of life, even leading to non-compliance of therapy. Therefore, nutraceuticals that stimulate/maintain hair growth can be proposed. Although nutraceuticals are often available without prescription and taken at the discretion of patients, physicians can be reluctant to recommend them, even as adjuvants, since potential interactions with endocrine therapy have not been fully elucidated. It is, therefore, important to understand the modus operandi of ingredients to be confident that their use will not interfere/interact with therapy. The aim is to improve clinical/healthcare outcomes by combining specific nutraceuticals with conventional care whilst avoiding detrimental interactions. This review presents the current understanding of nutraceuticals beneficial to hair wellness and outcomes concerning efficacy/safety in breast cancer patients. We will focus on describing endocrine therapy and the role of estrogens in cancer and hair growth before evaluating the effects of natural ingredients on breast cancer and hair growth.

show abstract

Pattern Alopecia during Hormonal Anticancer Therapy in Patients with Breast Cancer

Cited by 11 publications

References 13 publications

The role of CYP19A1 and ESR2 gene polymorphisms in female androgenetic alopecia in the Polish population

The role of CYP19A1 and ESR2 gene polymorphisms in female androgenetic alopecia in the Polish population

Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer

The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy

Contact Info

Product

Resources

About